Curr Opin Allergy Clin Immunol. 2024 Jul 30. doi: 10.1097/ACI.0000000000001009. Online ahead of print.
ABSTRACT
PURPOSE OF REVIEW: Epinephrine is the first line treatment for anaphylaxis, however, there are limited data to support this. This review examines data surrounding evidence for the use of epinephrine in anaphylaxis, data on prescription for and use of epinephrine autoinjectors, and data examining newer routes of delivery of epinephrine; with a focus on recent publications over the past few years.
RECENT FINDINGS: With recent epidemiologic studies of anaphylaxis and new forms of epinephrine being studied, new data on the effects of epinephrine are aiding in the understanding of epinephrine’s effects and the shortcomings of epinephrine both in its effect and utility in the real world.
SUMMARY: Epinephrine is still considered the first line therapy for anaphylaxis, and we are starting to have a better understanding of its effects in both healthy patients and those with anaphylaxis.
PMID:39079160 | DOI:10.1097/ACI.0000000000001009
